CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($0.98), $1.15 better than the analyst estimate of ($2.13). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.